Mymd Pharmaceuticals (NASDAQ:QCLS) Raised to Sell at Wall Street Zen

Mymd Pharmaceuticals (NASDAQ:QCLS) was upgraded by investment analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Mymd Pharmaceuticals presently has a consensus rating of “Sell”.

Mymd Pharmaceuticals Stock Performance

NASDAQ:QCLS opened at $0.76 on Friday. The stock has a market cap of $6.25 million, a PE ratio of -0.22 and a beta of 2.09. The firm has a 50-day simple moving average of $2.48. Mymd Pharmaceuticals has a twelve month low of $0.42 and a twelve month high of $8.94.

Mymd Pharmaceuticals (NASDAQ:QCLS) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.79) EPS for the quarter.

Mymd Pharmaceuticals Company Profile

MyMD Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapies for diseases associated with aging, chronic inflammation and immune-system dysfunction. Its research has centered on small-molecule drug candidates intended to regulate immune and metabolic pathways.

The company’s lead development program has included MYMD-1, an orally administered investigational compound studied for potential applications involving autoimmune disease, chronic inflammation and age-related conditions.